FOLH1 and prostate carcinoma: [68Ga]Ga-PSMA-11 (FDA approved December 2020) and [18F]DCFPyl (FDA approved May 2021) PET–CT scans were FDA approved for patients with suspected prostate cancer metastasis who are potentially curable by surgery or other therapy and for patients with suspected prostate cancer recurrence based on elevated PSA levels [16].